[1]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352-354.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
　Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(05):352-354.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
点击复制

白细胞介素-6与甲状腺疾病()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年05期
页码:
352-354
栏目:
综述
出版日期:
2016-09-20

文章信息/Info

Title:
Interleukin-6 and thyroid disease
作者:
郑仁东; 刘超
210028 南京,中国中医科学院江苏分院,南京中医药大学附属中西医结合医院内分泌代谢病院区
Author(s):
Zheng Rendong;  Liu Chao
Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medicine Science, Nanjing 210028, China
关键词:
白细胞介素-6;  Graves病;  桥本甲状腺炎;  甲状腺癌
Keywords:
Interleukin-6;  Graves' disease;  Hashimoto's thyroiditis;  Thyroid carcinoma
DOI:
10.3760/cma.j.issn.1673-4157.2016.05.18
摘要:
白细胞介素-6(IL-6)是一种多功能的细胞因子,参与细胞多种生物功能。IL-6的跨膜信号转导主要 分为两种,即经典通路和反式信号通路,通过IL-6/酪氨酸激酶-1(JAK-1)/信号转导和转录激活因子-3(STAT-3) 途径发挥其生物学作用。研究发现,IL-6能够抑制甲状腺细胞的分泌功能及摄碘功能。其次,在临床中发现,IL -6水平升高不仅与Graves病、桥本甲状腺炎显著相关,而且IL-6基因多态性与Graves病及桥本甲状腺炎的发病 关系密切。另外,研究发现,IL-6在甲状腺癌的发病机制中亦扮演重要的角色。
Abstract:
Interleukin(IL)-6 is a multifunctional cytokine involved in multiple biological functions of cells. Transmembrane signaling of IL-6 is divided into two types, the classical pathway and the trans-signaling pathway, and it plays biological effect via IL-6/Janus kinase-1 (JAK1)/signal transducers and activators of transcription-3(STAT3)signal pathway. The study found that IL-6 could inhibit the secretion of thyroid cells and iodine uptake function. Secondly, clinical study found that the level of IL-6 was increased significantly in Graves' disease and Hashimoto's thyroiditis, and IL-6 gene polymorphism was closely related with Graves' disease and Hashimoto's thyroiditis. In addition, IL-6 also plays an important role in the pathogenesis of thyroid carcinoma.

参考文献/References:

[1] Ataie-Kachoie P, Pourgholami MH, Richardson DR, et al. Gene of the month: interleukin 6(IL -6)[J].J Clin Pathol,2014,67(11):932-937. DOI: 10.1136/jclinpath-2014-202493.
[2] Rossi JF, Lu ZY, Jourdan M, et al. Interleukin-6 as a therapeutic target[J].Clin Cancer Res,2015,21(6):1248-1257. DOI: 10.1158/1078-0432.CCR-14-2291.
[3] Chang Q, Daly L, Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis[J].Semin Immunol,2014,26(1):48-53. DOI: 10.1016/j.smim.2014.01.007.
[4] Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system[J].Cytokine,2014,70(1):11-20. DOI: 10.1016/j.cyto.2014.05.024.
[5] Ernst M, Thiem S, Nguyen PM, et al. Epithelial gp130/Stat3 functions: an intestinal signaling node in health and disease[J].Semin Immunol,2014,26(1):29-37. DOI: 10.1016/j.smim.2013.12.006.
[6] Yamazaki K, Yamada E, Kanaji Y,et al. Interleukin-6(IL-6)inhibits thyroid function in the presence of soluble IL-6 receptor in cultured human thyroid follicles[J].Endocrinology,1996,137 (11):4857-4863.
[7] Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer [J].Cytokine,2010,50(3):229-233. DOI: 10.1016/j.cyto.2010.03.005.
[8] Nielsen CH, Brix TH, Leslie RG,et al. A role for autoantibodies in enhancement of pro- inflammatory cytokine responses to a self-antigen, thyroid peroxidase[J].Clin Immunol,2009,133 (2):218-227. DOI: 10.1016/j.clim.2009.07.014.
[9] acka K, Maciejewski A.Current views on the etiopathogenesis of autoimmune thyroiditis (Hashimoto's disease)[J].Pol Merkur Lekarski,2011,30(176):132-138.
[10] Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer [J].Cytokine,2010,50(3):229-233. DOI: 10.1016/j.cyto.2010.03.005.
[11] 李红林, 高美华, 郑云会,等. 细胞因子IFN-γ、IL-6、IL-17和TGF-β1在Graves病发病中 的作用[J].中国免疫学杂志, 2015(2): 253-256. DOI:10.3969/j.issn.1000-484X.2015.02.022.
[12] Zhang C, Zhang X, Ma L,et al. Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy[J].Endocrine,2012,41(2):248-255. DOI: 10.1007/s12020-012-9600-8.
[13] Planck T, Shahida B, Parikh H, et al. Smoking induces overexpression of immediate early genes in active Graves' ophthalmopathy[J].Thyroid,2014,24(10):1524-1532. DOI: 10.1089/thy.2014.0153.
[14] Popawska-Kita A, Szelachowska M, Modzelewska A,et al. Endothelial dysfunction in Graves' disease[J].Adv Med Sci,2013,58(1):31-37. DOI: 10.2478/v10039-012-0047-1.
[15] Kutluturk F, Yarman S, Sarvan FO, et al. Association of cytokine gene polymorphisms(IL6, IL10, TNF-α, TGF-β and IFN-γ)and Graves' disease in Turkish population[J].Endocr Metab Immune Disord Drug Targets,2013,13(2):163-167.
[16] Durães C, Moreira CS, Alvelos I, et al. Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease[J].PLoS One,2014,9(8):e105492. DOI: 10.1371/journal.pone.0105492.
[17] Ruggeri RM, Barresi G, Sciacchitano S,et al. Immunoexpression of the CD30 ligand/CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases[J].Histol Histopathol,2006,21(3):249-256.
[18] Siemińska L, Wojciechowska C, Kos-Kuda B, et al. Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto's thyroiditis [J].Endokrynol Pol,2010,61(1):112-116.
[19] 孙庆凯, 陈占玲, 李春华, 等. 白细胞介素6/转化生长因子-β信号异常在桥本甲状腺炎辅助性T细胞17/ 调节性T细胞失衡中的作用研究[J].中华内分泌代谢杂志, 2015, 31(4): 320-326. DOI:10.3760/cma.j.issn.1000-6699.2015.04.008.
[20] Inoue N, Watanabe M, Morita M, et al. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases[J].Clin Exp Immunol,2011,163(3):318-323. DOI: 10.1111/j.1365-2249.2010.04306.x.
[21] Wang SW, Sun YM. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer(Review)[J]. Int J Oncol,2014,44(4):1032-1040. DOI: 10.3892/ijo.2014.2259.
[22] Holmer R, Goumas FA, Waetzig GH, et al. Interleukin-6: a villain in the drama of pancreatic cancer development and progression[J].Hepatobiliary Pancreat Dis Int,2014,13(4):371-380.
[23] Kobawala TP, Trivedi TI, Gajjar KK,et al. Significance of interleukin-6 in papillary thyroid carcinoma[J].J Thyroid Res,2016,2016:6178921. DOI: 10.1155/2016/6178921.
[24] Ma X, Wehland M, Aleshcheva G,et al. Interleukin-6 expression under gravitational stress due to vibration and hypergravity in follicular thyroid cancer cells[J].PLoS One,2013,8 (7):e68140. DOI: 10.1371/journal.pone.0068140.
[25] Provatopoulou X, Georgiadou D, Sergentanis TN,et al. Interleukins as markers of inflammation in malignant and benign thyroid disease[J].Inflamm Res,2014,63(8):667-674.DOI: 10.1007/s00011-014-0739-z.
[26] 胡金华, 张耀晴, 艾瑞华, 等. 分化型甲状腺癌患者血清TNF-α、IL-6和VEGF表达与侵袭转移的相关性 分析[J]. 现代肿瘤医学, 2015, 23(6): 771-774.DOI: 10.3969/j.issn.1672-4992.2015.06.13.

相似文献/References:

[1]贾媛媛,陈莉丽.Th17细胞与Graves病及桥本甲状腺炎[J].国际内分泌代谢杂志,2014,(05):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
　Jia Yuanyuan,Chen Lili.Relationship between Th17 cells and Graves' disease,Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(05):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
[2]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
　Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(05):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
[3]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
　Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(05):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[4]郑仁东,茅晓东,张会峰,等.IL-6联合sIL-6R对人甲状腺细胞增殖 及相关基因表达的影响[J].国际内分泌代谢杂志,2017,37(02):82.[doi:10.3760/cma.j.issn.1673-4157.2017.02.003]
　Zheng Rendong,Mao Xiaodong,Zhang Huifeng,et al.Effects of IL-6 plus sIL-6R on cell proliferation and expression of related genes in human thyroid cells[J].International Journal of Endocrinology and Metabolism,2017,37(05):82.[doi:10.3760/cma.j.issn.1673-4157.2017.02.003]
[5]黄慧 胡欣 徐一娇 刘超.利妥昔单克隆抗体治疗Graves病的作用机制[J].国际内分泌代谢杂志,2018,38(02):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
　Huang Hui,Hu Xin,Xu Yijiao,et al.Mechanism of rituximab in the treatment of Graves' disease[J].International Journal of Endocrinology and Metabolism,2018,38(05):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
[6]苏亚峰 相萍萍 陈国芳 刘超.碘治疗Graves病的研究进展[J].国际内分泌代谢杂志,2019,39(01):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
　Su Yafeng,Xiang Pingping,Chen Guofang,et al.Research progress of iodine in treating Graves' disease[J].International Journal of Endocrinology and Metabolism,2019,39(05):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
[7]赫晓晴 单忠艳.肠道菌群与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2020,40(03):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
　He Xiaoqing,Shan Zhongyan.Gut microbiota and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(05):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
[8]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
　Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(05):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
[9]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
　Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(05):256.[doi:10.3760/cma.j.cn121383-20210420-04055]

备注/Memo

备注/Memo:
通信作者:刘超,Email:liuchao@nfmcn.com
更新日期/Last Update: 2016-11-20